STC2 activates PRMT5 to induce radioresistance through DNA damage repair and ferroptosis pathways in esophageal squamous cell carcinoma

Radioresistance is the major reason for the failure of radiotherapy in esophageal squamous cell carcinoma (ESCC). Previous evidence indicated that stanniocalcin 2 (STC2) participates in various biological processes of malignant tumors. However, researches on its effect on radioresistance in cancers are limited. In this study, STC2 was screened out by RNA-sequencing and bioinformatics analyses as a potential prognosis predictor of ESCC radiosensitivity and then was determined to facilitate radioresistance. We found that STC2 expression is increased in ESCC tissues compared to adjacent normal tissues, and a higher level of STC2 is associated with poor prognosis. Also, STC2 mRNA and protein expression levels were higher in radioresistant cells than in their parental cells. Further investigation revealed that STC2 could interact with protein methyltransferase 5 (PRMT5) and activate PRMT5, thus leading to the increased expression of symmetric dimethylation of histone H4 on Arg 3 (H4R3me2s). Mechanistically, STC2 can promote DDR through the homologous recombination and non-homologous end joining pathways by activating PRMT5. Meanwhile, STC2 can participate in SLC7A11-mediated ferroptosis in a PRMT5-dependent manner. Finally, these results were validated through in vivo ex-periments. These findings uncovered that STC2 might be an attractive therapeutic target to overcome ESCC radioresistance.

Automated summary

Radioresistance is a major challenge in esophageal squamous cell carcinoma (ESCC) radiotherapy, and this study identified STC2 as a potential predictor and facilitator of ESCC radioresistance. Increased STC2 expression in ESCC tissues was associated with poor prognosis. STC2 was found to interact with PRMT5 and activate it, leading to increased H4R3me2s expression. Moreover, STC2 promoted DNA damage repair and ferroptosis in a PRMT5-dependent manner.